Medpace Holdings, Inc. (MEDP)
POSITIVEFundamental
69
Price
$611.79
Market Cap
$17.31B
Part 1 · What the company is worth
Overview
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$2.78B
Trailing 12 months (through 6/30/2026)
Net Income
$492M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$682M
Total Equity
$459M
Total Liabilities
$1.52B
Current Ratio
0.73
Interest Coverage
-
Debt/EBITDA
0.24
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$847.98
Current Price
$611.79
Margin of Safety
+27.9%
Fair Value Range
$551.19 - $1144.77
Estimation Methods
Valuation Metrics
P/E Ratio
36.39
ROE
98.3%
P/B Ratio
39.89
P/FCF
24.49
Gross Margin
-
ROIC
74.1%
Profitability Radar
Value Creation (Economic Moat)
ROIC
74.1%
WACC
10.9%
ROIC − WACC
+63.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental Analysis Criteria
Passed (17)
- EPS shows upward trend
- Price CAGR 32.92%
- ROIC 74.1%
- P/FCF 24.49
- Debt/Equity ratio
- Operating Margin 21.0%
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- ROE 110.1%
- Revenue Growth 5Y 22.3%
- Earnings Surprise avg 7.5%
- PEG Ratio 1.05
- Earnings Quality (OCF/NI) 1.53
- Share Dilution -7.8%
- Piotroski F-Score 6/9
Failed (7)
- P/B Ratio 39.89
- Current Ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 35% Buy
- Net Margin Trend 17.7% vs 18.7%
Unavailable (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Buying back shares. Shareholder friendly
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. August James Troendle M.D. | CEO, President & Chairman | 69 |
| Mr. Kevin M. Brady | CFO & Treasurer | 50 |
| Mr. Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 56 |
| Mr. Brad W. Hansman | Executive Vice President of Operations | 42 |
| Ms. Lauren Morris | Associate Director of Investors Relations | - |
| Mr. Todd Meyers | Vice President of Business Development & Marketing | - |
| Mr. Weimin Gai MS | Senior Vice President of Biometrics | - |
| Mr. John T. Wynne MBA | Chief Business Officer | - |
| Ms. Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 64 |
| Ms. Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | - |
Audit Risk
6
Board Risk
8
Compensation Risk
4
Shareholder Rights Risk
5
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for MEDP, sourced from Markets Gazette.